简介:Objective:ToinvestigatetheeffectsofCAL-101,particularlywhencombinedwithbortezomib(BTZ)onmantlecelllymphoma(MCL)cells,andtoexploreitsrelativemechanisms.Methods:MTTassaywasappliedtodetecttheinhibitoryeffectsofdifferentconcentrationsofCAL-101.MCLcellsweredividedintofourgroups:controlgroup,CAL-101group,BTZgroup,andCAL-101/BTZgroup.TheexpressionofPI3K-p110σ,AKT,ERK,p-AKTandp-ERKweredetectedbyWesternblot.TheapoptosisratesofCAL-101group,BTZgroup,andcombinationgroupweredetectedbyflowcytometry.Thelocationchangesofnuclearfactorkappa-B(NF-κB)of4groupswasinvestigatedbyNF-κBKitexploring.Westernblotwasappliedtodetectthelevelsofcaspase-3andthephosphorylationofAKTindifferentgroups.Results:CAL-101dose-andtime-dependentlyinducedreductioninMCLcellviability.CAL-101combinedwithBTZenhancedthereductionincellviabilityandapoptosis.WesternblotanalysisshowedthatCAL-101significantlyblockedthePI3K/AKTandERKsignalingpathwayinMCLcells.ThecombinationtherapycontributedtotheinactivationofNF-κBandAKTinMCLcelllines.However,cleavedcaspase-3wasup-regulatedaftercombinedtreatment.Conclusion:OurstudyshowedthatPI3K/p110σisanoveltherapeutictargetinMCL,andtheunderlyingmechanismcouldbetheblockingofthePI3K/AKTandERKsignalingpathways.ThesefindingsprovidedabasisforclinicalevaluationofCAL-101andarationaleforitsapplicationincombinationtherapy,particularlywithBTZ.
简介:目的探讨胃癌患者手术前后血浆miRNA-101、miRNA-21表达水平及其临床意义。方法选取50例行胃癌根治术的胃癌患者为胃癌组,另选取同期健康体检者50例为健康对照组,分别于术前、术后1周及术后1个月检测胃癌患者,体检时检测健康体检者血浆中miRNA-101、miRNA-21表达水平;并比较不同临床特征胃癌患者的血浆miRNA-101、miRNA-21表达水平。结果术前胃癌组患者血浆miRNA-101相对表达量明显低于健康对照组,miRNA-21相对表达量明显高于健康对照组(P﹤0.01)。与术前比较,术后1周及术后1个月胃癌患者血浆miRNA-101相对表达量逐渐增高,血浆miRNA-21相对表达量逐渐降低(P﹤0.05)。不同分化程度、TNM分期、淋巴结转移情况的胃癌患者术前血浆miRNA-101、miRNA-21相对表达量比较,差异均有统计学意义(P﹤0.05)。结论胃癌患者血浆miRNA-101、miRNA-21可作为胃癌潜在的生物标志物,有望成为胃癌诊断、手术疗效评估的新手段。
简介:目的:回顾性分析结合和未结合骨髓单个核细胞(bonemarrowmononuclearcells,BMMCs)移植的打压植骨治疗骨循环研究协会(associationresearchcirculationosseous,ARCO)分期IIB期、IIC期股骨头坏死的疗效。方法34例(53髋)非创伤性股骨头坏死(osteonecrosisofthefemoralhead,ONFH)手术患者获得随访。男27例,女7例。手术时年龄28~42岁,平均38.1岁。手术方法:微创扩大髓芯减压坏死灶清除、人工骨打压植入。BMMCs移植组加入5ml浓集后的BMMCs,单纯植骨组未加入BMMCs。采用Harris评分系统评估术后患髋功能改善情况,应用视觉模拟标尺法(visualanaloguescale,VAS)进行临床疼痛测定,影像学按股骨头是否塌陷及病灶修复情况评定。结果两组患者整体术后终末随访Harris评分较术前显著提高(64.1±4.6)分vs(78.8±4.8)分,(P=0.0000)。与单纯植骨组相比,BMMCs移植组术后终末随访Harris评分较术前提高幅度更明显(28.6±0.5)%vs(18.4±1.7)%,(P<0.0001)。两组患者整体术后终末随访VAS评分较术前显著降低(6.3±0.9)分vs2.6±0.7)分,(P=0.0000)。与单纯植骨组相比,BMMCs移植组术后终末随访VAS评分较术前降低幅度更明显(-66.3±1.4)%vs(-51.7±2.9)%,(P<0.0001)。BMMCs移植组临床成功率(21/26)高于单纯植骨组(10/27),差异有统计学意义(P=0.001)。BMMCs移植组放射学成功率(23/26)高于单纯植骨组(11/27),差异有统计学意义(P=0.001)。结论微创扩大髓芯减压坏死灶清除、人工骨打压植入术在选择合适的中早期非创伤性ONFH(ARCO分期IIB期、IIC期)可获得优良的中期疗效。结合浓集BMMCs移植可提高保留关节手术疗效和骨修复质量。